Innova CaptabNSE:INNOVACAP -0.15%54 Interest Coverage is 11.69 as of Mar. 2026, which is 4% above its 10-year median of 11.29. GuruFocus rates NSE:INNOVACAP with a GF Score™ of 54/100. The stock has 6 warning signs investors should review. Among 687 Drug Manufacturers companies, Innova Captab ranks worse than 52.26% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Innova Captab's
Operating Income
for the
three
months ended in Mar. 2026 was ₹537 Mil. Innova Captab's Interest Expense for the
three
months ended in Mar. 2026 was ₹-46 Mil.
Innova Captab's interest coverage for the quarter that ended in Mar. 2026 was 11.69.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Innova Captab's Interest Coverage or its related term are showing as below:
NSE:INNOVACAP'
s Interest Coverage Range Over the Past 10 Years
Min: 5.55 Med: 11.29 Max: 73.73
Current: 11.44
NSE:INNOVACAP's Interest Coverage is ranked worse than 52.26% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs NSE:INNOVACAP: 11.44
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Innova Captab Interest Coverage Related Terms
Innova Captab Interest Coverage Historical Data
* Premium members only.
The historical data trend for Innova Captab's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:INNOVACAP vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Innova Captab's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innova Captab (NSE:INNOVACAP) has a Interest Coverage of 11.69 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Innova Captab and its competitors. This is near median its historical median of 11.29. Over the past decade, Innova Captab's Interest Coverage has ranged from 5.55 to 73.73. According to the industry distribution chart, Innova Captab ranks #359 out of 687 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Innova Captab's Interest Coverage too high?
Innova Captab's current Interest Coverage of 11.69 is near median its 10-year median of 11.29. Over the past 10 years, this metric has ranged from a low of 5.55 to a high of 73.73. The Drug Manufacturers industry median Interest Coverage is 12.75. Innova Captab's value of 11.69 is 8.3% below this industry median. Based on the distribution chart, Innova Captab ranks #359 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Innova Captab has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #359 out of 687 companies for Interest Coverage. This places Innova Captab in the lower half of its industry. The industry median Interest Coverage is 12.75. Innova Captab's value of 11.69 is 8.3% below this benchmark. Historically, Innova Captab's own Interest Coverage has ranged from 5.55 to 73.73 over the past decade. While the company's 10-year median is 11.29 vs. the industry median of 12.75, Innova Captab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current Interest Coverage of 11.69 is 8.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current Interest Coverage is 11.69, which is near median its own 10-year median of 11.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Innova Captab (NSE:INNOVACAP) has a current Interest Coverage of 11.69. The current Interest Coverage is 11.69, which is near median its 10-year median of 11.29 and 8.3% below the Drug Manufacturers industry median of 12.75. Innova Captab's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current Interest Coverage is 11.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
54GF Score
Get the complete analysis for NSE:INNOVACAP
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INNOVACAP has been successfully added to your 
